GlassScriptPhysician profile
Charles Patrick Mcdonald
NPI 1164061834
$1,644.43
in general payments reported to CMS, 2019-2025
30 companies · $77.71 in 2025
The $77.71 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,182 · 2022: $83.32 · 2023: $211 · 2024: $90.58 · 2025: $77.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $378.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $147.02 | 2021 | |
| Ferring Pharmaceuticals INC. | $135.13 | 2022-2023 | Euflexxa |
| Abbvie INC. | $122.78 | 2021 | |
| Novo Nordisk INC | $114.06 | 2021-2022 | |
| Fidia Pharma USA INC. | $102.56 | 2022-2025 | Hymovis, Triluron, Hymhyn |
| Astrazeneca Pharmaceuticals LP | $73.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.28 | 2021 | |
| Amgen INC. | $70.06 | 2021-2024 | Krystexxa |
| Amarin Pharma, INC. | $69.65 | 2021 | |
| Depuy Synthes Sales INC. | $69.51 | 2024-2025 | Monovisc, Orthovisc |
| Merck Sharp & Dohme LLC | $68.77 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $62.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.31 | 2021 | |
| Pfizer INC. | $55.90 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $49.65 | 2023 | Zilretta, Exparel, Iovera |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $47.80 | 2021 | |
| Glaxosmithkline, LLC. | $43.22 | 2021 | |
| Novartis Pharmaceuticals Corporation | $41.94 | 2021 | |
| Corcept Therapeutics | $32.93 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $30.67 | 2021 | |
| Esperion Therapeutics, INC. | $27.96 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.60 | 2021 | |
| Insulet Corporation | $25.91 | 2021 | |
| Cvrx, INC. | $16.52 | 2025 | Barostim Neo System |
| Eisai INC. | $16.37 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.75 | 2021 | |
| Smith+Nephew, INC. | $12.77 | 2023 | Pico |
| Upsher-Smith Laboratories LLC | $12.21 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.95 | 2021 | |
| Xeris Pharmaceuticals, INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.